Longeveron Inc. 2022 Form 10-K Summary
Business context and reporting period
Longeveron is a clinical-stage biotechnology company developing Lomecel-B, an allogeneic bone-marrow-derived medicinal signaling cell therapy. The company is pursuing indications in hypoplastic left heart syndrome (HLHS), aging-related frailty and Alzheimer’s disease. The filing covers the fiscal year ended December 31, 2022; the source does not provide separate fourth-quarter financial results.
- Key programs included the Phase 2 ELPIS II HLHS trial, a Japanese Phase 2 aging-related frailty trial, and a Phase 2 Alzheimer’s disease trial.
- Lomecel-B has not received regulatory approval for commercial sale. Revenue was generated from grants, the Bahamas Registry Trial and occasional contract manufacturing services.
- As of December 31, 2022, the company had 19 full-time employees, two part-time employees and two consultants.
Financial performance and liquidity
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $1.222 million | $1.306 million | Down 6% |
| Gross profit | $0.497 million | $0.590 million | Down 16% |
| Gross margin | Approximately 41% | Approximately 45% | Down approximately 4 percentage points |
| Operating expenses | $18.540 million | $18.046 million | Up 3% |
| Loss from operations | $(18.043) million | $(17.456) million | Loss increased $0.587 million |
| Net loss | $(18.835) million | $(17.045) million | Loss increased 11% |
| Basic and diluted loss per share | $(0.90) | $(0.90) | Flat |
| Net cash used in operating activities | $(13.969) million | $(9.636) million | Use increased $4.333 million |
- Revenue consisted of $0.282 million of grant revenue and $0.940 million of clinical trial revenue. Grant revenue declined 53%, while Bahamas Registry Trial revenue increased 33%.
- Research and development expense increased 32% to $9.370 million, primarily from higher non-grant-funded clinical trial costs. Clinical trial expenses were $4.170 million, compared with $1.935 million in 2021.
- General and administrative expense declined 17% to $8.119 million, primarily because equity-based compensation decreased by approximately $3.0 million.
- The 2022 net loss included a $1.398 million accrued expense related to a proposed securities litigation settlement. In 2021, the company recorded $0.300 million of Paycheck Protection Program loan forgiveness, which did not recur.
- Cash and cash equivalents were $10.503 million and marketable securities were $9.155 million at year-end, for approximately $19.7 million of combined cash and securities as disclosed by management. Working capital was approximately $15.4 million.
- Total liabilities were $6.910 million. The company reported no outstanding debt financing, but had $2.605 million of long-term operating lease liabilities and approximately $3.027 million of remaining operating lease obligations.
- Accumulated deficit was $62.773 million at December 31, 2022, compared with $43.938 million at December 31, 2021.
Material changes versus the prior comparable period
- Operating cash usage rose substantially as clinical development spending increased.
- Revenue mix shifted away from grants toward Bahamas Registry Trial revenue, reducing the quality and predictability of revenue support from grants.
- Research and development spending increased by $2.278 million, while general and administrative spending decreased by $1.621 million.
- Cash and cash equivalents declined from $25.658 million to $10.503 million, while marketable securities remained broadly comparable on the balance sheet.
- Share-based compensation expense declined from approximately $6.4 million to $2.3 million, partially offsetting higher cash-based development costs.
- During 2022, 811,749 Class B shares were exchanged for Class A shares. At year-end, two Class B holders controlled approximately 92% of combined voting power.
Guidance, outlook, risks and unusual items
- Management stated that existing cash, cash equivalents and investments were expected to fund operating expenses and capital expenditures through the second half of 2024, but cautioned that actual cash usage could be faster than projected. The financial statements also state that resources were expected to fund at least the next 12 months from issuance.
- The company expects continued operating losses and additional capital needs. It has no credit facility or committed sources of capital and may seek equity, debt, grants, collaborations or licensing transactions.
- ELPIS II enrollment was insufficient for management to project a completion date. The company planned to add an eighth site to improve enrollment.
- The Japanese aging-related frailty trial was expected to dose its first patient in the first quarter of 2023. Regulatory approval for frailty remains uncertain because the indication lacks a generally accepted definition and requires further discussions with the FDA and PMDA.
- Lomecel-B received FDA Fast Track designation for HLHS in August 2022 and previously received Rare Pediatric Disease and Orphan Drug designations. These designations do not assure approval, a priority review voucher or market exclusivity.
- The proposed securities lawsuit settlement was $1.4 million, subject to court approval. The amount was accrued at year-end and recorded as a non-operating lawsuit expense.
- The company relies on third parties for bone marrow, biologic media, clinical research services and other specialized supplies. Manufacturing scale-up, donor supply, product quality, clinical enrollment and regulatory approval remain significant execution risks.
- The Alzheimer’s Association grant agreement may require revenue-sharing or other payments related to resulting products or inventions, potentially up to five times the award amount, although the payment terms are not currently defined.
- As a clinical-stage company with no approved products, Longeveron faces substantial risks of clinical failure, regulatory delay, limited reimbursement, intellectual-property challenges, dilution from future financings and inability to achieve profitability.
- Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2022, and no material weaknesses.
Important facts for investors to verify
- Reconcile the company’s cash runway assumptions with the $13.969 million of 2022 operating cash burn and expected clinical development spending.
- Monitor future financing requirements, potential dilution, warrant repricing provisions and the availability of the company’s Form S-3 shelf registration.
- Track enrollment, timing and data quality for ELPIS II, the Japan frailty study and the Alzheimer’s Phase 2 study.
- Confirm final court approval and payment timing for the proposed $1.4 million securities litigation settlement.
- Assess whether grant funding, Bahamas Registry Trial revenue and contract manufacturing revenue can offset increasing research and development costs.
- Review regulatory feedback regarding the definition, endpoints and approval pathway for aging-related frailty.
- Evaluate the company’s ability to scale cGMP manufacturing and maintain adequate donor, raw-material and clinical-site supply.